Abstract

The article investigated the issues of the arrangement of personalized selection of drugs for cancer patients. The potential economic efficiency of the use of molecular genetic studies for the prescription of drugs and the cost-effectiveness was calculated using antitumor drugs as an example. A sociological survey of medical professionals on personalized selection of drugs in medical practice was conducted. A statistical link has been established between the practice of prescribing drugs according to the pharmacogenetic testing results and such indicators as side effects monitoring, pharmacoeconomic analysis of the use of drugs in medical organizations. The structural-logical scheme of interaction between the subjects of healthcare and the drug provision system for personalized therapeutic drug management for cancer patients has been developed based on scientific research.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.